Council of the European Union

Brussels, 23 December 2025
(OR. en)

17109/25
ADD 1

Interinstitutional File:
2025/0415 (NLE)

CORDROGUE 162
SAN 861
RELEX 1721
EUDA
EUROPOL

PROPOSAL

From:	Secretary-General of the European Commission, signed by Ms Martine DEPREZ, Director
date of receipt:	18 December 2025
To:	Ms Thérèse BLANCHET, Secretary-General of the Council of the European Union
No. Cion doc.:	COM(2025) 777 annex
Subject:	ANNEX to the Proposal for a COUNCIL DECISION on the position to be taken on behalf of the European Union in the sixty-ninth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971

Delegations will find attached document COM(2025) 777 annex.

Encl.: COM(2025) 777 annex

EUROPEAN
COMMISSION

Brussels, 18.12.2025
COM(2025) 777 final

ANNEX

ANNEX

to the

Proposal for a

COUNCIL DECISION

on the position to be taken on behalf of the European Union in the sixty-ninth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971

Annex

1. Position to be taken by the Member States which are members of the Commission on Narcotic Drugs, acting jointly, in the interest of the Union during the sixty-ninth session of the Commission on Narcotic Drugs planned to take place from 9 to 13 March 2026 regarding changes in the scope of control of substances:

1.1. *N*-pyrrolidino isotonitazene (Isotonitazepyne) is to be included in Schedule I to the Convention on Narcotic Drugs (IUPAC name: 5-nitro-2-({4-[(propan-2-yl)oxy]phenyl}methyl)-1-[2-(pyrrolidin-1-yl)ethyl]-1*H*-1,3-benzimidazole).

1.2. *N*-desethyl etonitazene is to be included in Schedule I to the Convention on Narcotic Drugs (IUPAC name: 2-[2-[(4-ethoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]-*N*-ethyl-ethanamine).

1.3. MDMB-FUBINACA is to be included in Schedule II to the Convention on Psychotropic Substances (IUPAC name: methyl 2-[[1-[(4-fluorophenyl)methyl]indazole-3-carbonyl]amino]-3,3-dimethyl-butanoate).